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The standard of care therapy of chronic hepatitis C with the combination of pegylated inter-
feron  and ribavirin for 24 or 48 weeks was a remarkable accomplishment of the past decade.
However,  sustained virological responses rates of about 80% (genotypes 2–3) and 50% (geno-
type  1) were not satisfactory especially for patients infected with genotype 1. Important
advances  in the biology of HCV have made possible the development of the direct-acting
antiviral  agents boceprevir and telaprevir with substantial increase in the rates of sustained
virological  response with shorter duration of therapy for a large number of patients. How-
ever,  the complexity of triple therapy is higher and several new side effects are expected
suggesting  greater expertise in the patient management. Anemia and disgeusia are fre-
quent  with boceprevir while cutaneous rash, ranging from mild to severe, is expected with
telaprevir.  Higher risk of drug–drug interactions demand further clinical consideration of
the previous well-known adverse events of pegylated interferon and ribavirin. Identiﬁcationand  prompt management of these potential new problems with boceprevir and telaprevir
are  crucial in clinical practice for optimizing treatment and assuring safety outcomes to
HCV-genotype  1 patients.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
The standard of care (SOC) therapy of chronic hepatitis C with
the  combination of pegylated interferon (PegIFN) and ribavi-
rin  (RBV) for 24 or 48 weeks was  a remarkable therapeutic
accomplishment of the past era. However, sustained virolo-
gical  responses (SVR) rates of about 80% (genotypes 2–3) and
∗ Corresponding author at: Faculdade de Medicina da UFMG, Avenida A
E-mail address: teixeira@medicina.ufmg.br (R. Teixeira).
1413-8670 ©  2013 Elsevier Editora Ltda. 
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Este é um artigo Open Access sob a licença50% (genotype 1) were not satisfactory especially for patients
infected  with genotype 1.1 Important advances in the knowl-
edge  of the structure of HCV proteins, in conjunction with
the  development of a subgenomic replicon system and a cell
culture  model that enables productive HCV infection,2,3 havelfredo Balena, 190/246, Belo Horizonte, MG  30130-100, Brazil.
made  possible the development of new direct-acting antivi-
ral  agents (DAAs) with substantial increase of SVR rates with
shorter  duration of therapy for a large number of patients.4
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ecently, new treatments with the protease inhibitors (PIs)
oceprevir  (BOC) and telaprevir (TVR) have brought additional
hances  of cure. However, the complexity of triple therapy
s  higher and several new side effects and risk of drug–drug
nteractions are anticipated. Identiﬁcation and appropriate
anagement of these potential problems are crucial in clinical
ractice  for optimizing treatment and assuring safety out-
omes  to HCV patients. Therefore, the purpose of this paper is
o provide an overview of clinical data regarding safety aspects
f  PIs including adverse events (AEs) and drug-to-drug inter-
ctions.
roteases  as  potential  targets  of  DAAs
ach step of HCV life cycle offers a potential target for DAA
herapy.5 The NS2 and NS3/4A are viral peptidases involved
n  the post-translational processing of HCV proteins. NS3
s  a multifunctional viral protein containing a serine pro-
ease  domain in its N-terminal third (approximately 180
mino  acids) and a helicase NTPase domain in its C-terminal
wo-third, and NS4A is a cofactor of its proteinase activity.
S3  must assemble with its cofactor NS4A to catalyze HCV
olyprotein cleavage.
Preclinical  data has demonstrated experimentally that
CV  containing defective NS3/4A activity could not replicate.6
his concept was  the basis for the recent development
f two ﬁrst-generation NS3/4A anti-protease agents – TVR
Incivek®; Vertex Pharmaceuticals, Cambridge, MA,  USA).7 and
OC  (Victrelis®; Merck, Kenilworth, NY, USA),8 both recently
pproved to treat chronic hepatitis in Europe, USA and in
razil.  When used in combination with PegIFN and RBV, these
Is  improve substantially the SVR rates in both treatment-
aïve patients and in those with previous virological failure.
evertheless, the addition of these new agents increased
he  complexity of HCV treatment, as new AEs and several
rug–drug interactions, leading to the discontinuation of all
ntiviral  treatments in 9–20% of cases.9–13 In addition, resis-
ance  mutations are a new main concern as they are more
ikely  to develop with ongoing exposure to PIs. Thus, updated
uidelines of HCV treatment have set up strict stopping rules
ased  on inadequate virological responses or severe side-
ffects.1,14
TVR is bioavailable and absorbed in the small intestine.15
or optimal exposure, TVR must be taken with food rich in fat.
ystemic exposure (area under the curve – AUC) is increased by
37% with a standard fat meal (533 kcal and 21 g fat) compared
ith  the fasted state.16 Clinical trials have also demonstrated
hat BOC AUC increased up to 65% when taken with food, but
ype  of meal and timing are not essential.17
dverse  events  with  DAAs
he triple therapy with BOC or TVR has distinctive AEs. The
ost  important side-effects associated with BOC are ane-
ia,  neutropenia and dysgeusia (altered sense of taste). With
VR,  the AEs are slightly different from BOC as skin rash
nd  anorectal symptoms (discomfort and pruritus) are more
requent.  Dose reductions of IPs should not be used in the3;1 7(2):194–204  195
management of AEs, as suboptimal doses of these drugs will
promote  the emergence of resistant HCV species resulting in
treatment failure.
Anemia  with  PI  treatment
Anemia, deﬁned as hemoglobin levels below 10 g/dL, is a rec-
ognized  RBV related event with considerable increased rate by
the addition of TVR or BOC to the SOC HCV treatment. In clin-
ical  trials, triple therapy resulted in a 20–26% increase in the
rate  of anemia with PIs compared to SOC.14 The frequency of
anemia  is higher for triple therapy with BOC as compared to
TVR  (about 50% and 40%, respectively). It seems to result from
bone-marrow suppressive effect and not haemolysis.18
The impact of anemia on the SVR rate was  distinct for
the  two drugs in clinical trials. A recent pooled retrospective
analysis of two phase 3 studies (ADVANCE and ILLUMINATE)
evaluated efﬁcacy outcomes of TVR in relation to the occur-
rence  of anemia in 1239 patients.19 The frequency of anemia
was  41% and 26% in patients with triple therapy with TVR and
SOC,  respectively. SVR rates in patients with anemia were  74%
and 50% with triple therapy and SOC, respectively. Conversely,
SVR  rates of patients without anemia were  73% and 41%
with  triple therapy and SOC treatment. These data strongly
suggested that anemia had no effect on SVR rates in treat-
ment  naïve patients. Although anemia was  more  frequent in
patients who received a TVR-based regimen as compared to
patients  on SOC treatment, the hemoglobin values gradually
improved after the end of TVR at week 12 and were  similar
to  those on SOC by week 20.19 In addition, patients with TVR-
based  therapy and SOC who developed anemia had 72% and
58%  of RBV dose reduction due to AEs, compared to 11% and
6%  of patients without anemia. SVR was  achieved by 76% and
54%  of patients with RBV dose reduction in the TVR-based
therapy and SOC, respectively, compared with 72% and 41%
of  patients without RBV dose reduction in TVR-based therapy
and  SOC, respectively. This data suggested that management
of  treatment-related anemia with dose reduction of RBV did
not  impact SVR with TVR-based therapy.19
The relationship of anemia in BOC-based regimen with
SVR  was  also investigated in a retrospective analysis of 1097
treatment-naïve and 403 previous-treatment failure patients
included  in BOC trials. Anemia occurred in 49% and in 29.7%
of  patients treated with BOC regimen and SOC, respectively.
The  management of anemia consisted of EPO use by 78.5% of
anemic  patients on BOC regimens and 29% of those treated
with  SOC. In contrast to that observed in TVR trials, the
SVR  rate was  higher in patients who developed anemia com-
pared  to patients without anemia in both naïve or experienced
patients.19 However, since about 80% of anemic patients took
EPO  in BOC trials, the relationship of SVR and reduction of RBV,
anemia  and EPO use has not been completely established with
TVR  regimens so far.
According  to the recent UK guidelines for the use
of  the PIs in HCV treatment14 management of anemia
(Hb < 10 g/dL) and signiﬁcant neutropenia (absolute neutrophil
3count  < 750/mm ) should be conducted as follows: (a) RBV dose
should  be started at full treatment dose and dose reduction
instituted for anemia at decrements of 200 g; (b) reduction in
dose  of IFN, if bone marrow suppression is evident; (c) EPO
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administration may  be considered and used until Hb > 12 g/dL;
supportive  treatment with blood transfusion should be con-
sidered  in extreme circumstances and signiﬁcant neutropenia
should  be managed according to current practice for SOC
treatment. In addition, consideration should be given to dose
reduction  of PegIFN. Importantly, the dose of PI should not
be  reduced for managing neutropenia or bone marrow sup-
pression.  If required due to the severity of neutropenia, the PI
should be stopped completely.
Dermatological  events  during  PI  treatment
The typical dermatological reactions with SOC consist of gen-
eralized  pruritus and skin xerosis, with eczematiform lesions
accentuated  by erythematous papules and microvesicles that
are  often excoriated, with predominance on the extremities
and  truncal skin sites exposed to friction.20
Use of DAAs results in additional skin disorders. Higher
frequency and severity of dermatological reactions have been
reported with TVR21–23 and infrequently with BOC,24,25 as part
of  triple therapy regimens. This fact is especially important in
clinical practice as extra patient management considerations
are  required by HCV-treating physicians.
A pooled analysis of the dermatological safety proﬁle
among 1346 patients who  received at least one dose of TVR and
764  patients who received at least one dose of placebo in ﬁve
placebo-controlled phase II/III trials of TVR,9,10,12,22 rash and
pruritus were  observed in 55% and 51% of patients treated with
TVR-based  regimen compared to 33% and 26% with placebo.
In  TVR trials, rash events were  graded by severity into three
grades21,22 (Table 1). More  than 90% of rash events related to
TVR  were  Grade 1 or 2 (mild/moderate) and did not progress.
The  extent of rash in TVR clinical trials grades 1, 2, and 3
were  37%, 14% and 5%, respectively. In 92% of patients with
rash,  no progression to a more  severe grade was observed.
Table 1 – Grading and management of Telaprevir rash severity.
Grade Description 
Grade 1 – mild Localized skin eruption and/or limited skin erupt
associated pruritus
Grade 2 – moderate Diffuse skin eruption involving up to 50% of body
without superﬁcial skin peeling, pruritus, or muc
involvement with no ulceration
Grade 3 – severe Generalized rash involving EITHER > 50% of body 
presenting with any of the following characterist
• Vesicles or bullae
•  Superﬁcial ulceration of mucous membranes
• Epidermal detachment
•  Typical or atypical target lesions
• Palpable purpura/non-blanching erythema
Life-threatening or
systemic
reactions
Stevens–Johnson  syndrome (SJS), toxic epiderma
drug reaction with eosinophilia and systemic sym
that  requires therapy with systemic corticosteroi
a Phase III telaprevir trials.21,22 1 3;1  7(2):194–204
Approximately 6% of all patients required discontinuation of
TVR  as a result of skin lesions that resolved with discontinua-
tion  of the drug. About 50% of all rash events started during the
ﬁrst  four weeks of TVR use, with the remaining 50% starting
until  week 12. The median time to onset of rash of any grade
was  25 days (ranging from 1 to 350 days), suggesting that it can
occur at any time during treatment.26 After stopping TVR at
week  12, the incidence of rash was  comparable between TVR
and  placebo-treated patients.27
Based on a systematic retrospective assessment review of
photographs  and biopsies of all rash events reported in Phase
III  TVR trials, the expert panel of dermatologists concluded
that  the visual appearance and histopathology of rash asso-
ciated  with TVR are comparable to the rash associated with
SOC,  though TVR-associated rashes were of increased severity
and  extent, which may  occur any time during treatment, and
resolve  over weeks after discontinuation of TVR. In addition,
the  biopsies were not suggestive of vasculitis.26
There is no worldwide consensus on the deﬁnition of
severe  cutaneous adverse reaction (SCAR); however, the con-
sensus  panel deﬁned that dermatological conditions that are
life-threatening and frequently attributed to drug therapy
were  reported as SCAR, including Stevens–Johnson syndrome
(SJS),  toxic epidermal necrolysis (TEN), drug reaction with
eosinophilia and systemic symptoms (DRESS), and acute
generalized exanthematous pustulosis (AGEP). Clinical inves-
tigators  in the TVR development program reported six subjects
with  SCAR and the panel assessed four as suspected SCAR (one
deﬁnitive  SJS, one deﬁnitive DRESS and two possible DRESS
cases).  Nine out of 11 suspected DRESS cases did not have
systemic organ involvement while organ involvement was
unconﬁrmed  in two (FDA accessed 12 March, 2012). SJS and
TEN  are very acute events, with a mortality rate of 25% dur-
ing  hospitalization. DRESS is more  progressive and less severe,
with  mortality rate around 10%.28
a
Management
ion with or without Telaprevir interruption generally is not
necessary
 surface area with or
ous membrane
Telaprevir  interruption generally is not
necessary
• For progressive eruption telaprevir
should  be discontinued ﬁrst.
•  Consider interrupting ribavirin and/or
peginterferon if no improvement in
eruption within 7 days of stopping
telaprevir,  or earlier if rash worsens.
surface area OR rash
ics:
Telaprevir  must be stopped immediately
•  Interrupt ribavirin and/or peginterferon
if no improvements in rash with 7 days of
stopping telaprevir, or earlier if rash
worsens.
l necrolysis (TEN),
ptoms (DRESS), rash
ds
Permanent  discontinuation of all
treatment
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Fig. 1 – Practical scheme for determining percentages of
body  surface area (BSA) affected by skin reactions in adults.
Adult Surface %
Arm 9
Head 9
Neck 1
Leg 18
Face/anterior trunk 18
Face/posterior trunk 18
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Table 2 – Biological signs and symptoms to distinguish
among the most severe telaprevir-related cutaneous
adverse reactions (SCARS): drug reaction with
eosinophilia and systemic symptoms (DRESS),
Stevens–Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN).26
DRESS SJS or TEN
Onset from 5–10 weeks after drug
use
Rapidly  progressive
exanthema
Rapidly progressive exanthema in
>50% of BSAa
Skin pain
Presence of bullae and vesicles Mucosal involvement at
more  than two sites
Prolonged fever in general >38.5 ◦C Blisters or epidermal
detachment
Facial edema Atypical target lesions
Enlarged lymph nodes
Eosinophilia  >10%
Atypical  lymphocytes
Rises  in ALT, AP (≥2 times upper
normal  limit)
Rise  in creatinine (≥150% basal
level)
a BSA: body surface area.
any  case is deﬁnitive. Hence, the major aim is not to underesti-The mechanism of TVR-related rash remains unknown and
o  predictors have been identiﬁed. An analysis of multiple
LA  alleles performed to determine if the genetic background
ay  increase or decrease the risk of developing a rash during
VR-based  regimen did not reveal a strong association of any
LA allele with rash.26
The second dermatological AEs associated with TVR was
ruritus,  in general associated with rash but could also be seen
ithout  it.
reatment  and  management  of  rash
he recommendations for grading and monitoring the derma-
ological  reactions and for discontinuation of TVR, PegIFN and
BV  have been based on the extension and features of derma-
ological  reactions. An estimate of body surface area (BSA) has
een used as an indicator of the severity of a dermatological
eaction (Fig. 1).
One  important point to HCV-treating physicians is to be
ble  to distinguish between usual dermatitis and SCAR. The
ost  frequent TVR-dermatitis is a single entity that generally
egins  during the ﬁrst four weeks of therapy, but can occur
t  any time during treatment. The reaction is an eczema-
ous  dermatitis similar to that observed with SOC, but is more
requent  and severe with TVR-regimen. Typical rash include
ruritus  and skin dryness and is stable. The continuation
f  the triple therapy is possible in Grades 1 and 2 or evenin Grade 3 with appropriate management. However, in the
rare  SCAR presentation, potentially life-threatening if unrec-
ognized  or unmanaged, immediate treatment discontinuation
is  mandatory.27
According to some authors27 some cases of Grade 3 der-
matitis reaction affecting more  than 50% of body surface
but  with no signs of SJS, TEN, DRESS, EM or AGEP, may  be
manageable using topical corticosteroids without treatment
discontinuation. In such cases, hospitalization is required to
close follow up and intervention in case of signs of pro-
gression. Experienced dermatologists should be responsible
for  patient management. The maintenance of Peg/RBV was
allowed  in Phase III studies of TVR after the cessation of this
drug,  to keep the chance of SVR while minimizing the risk of
DRESS  or SJS. However, the less common but potentially life-
threatening  reactions such as SJS, TEN and DRESS required
prompt  cessation of all drugs.27 Differential diagnosis based
on  biological signs and symptoms has been suggested27 to
help  physicians distinguishing between TVR-related dermati-
tis,  where antiviral treatment can be continued and supportive
treatment given, and the less common but potentially harmful
SJS  and DRESS reactions (Table 2).
In the case of rash grade 1 or 2, patients can beneﬁt from
skin  care that may  limit symptoms and allow antiviral therapy
to  be continued for as long as possible optimizing the likeli-
hood  for viral clearance with TVR-based therapy. Good skin
care  practices include prophylactic application of emollient
creams and lipid-rich lotions, rather than aqueous lotions or
ointments after shower or bath, when the skin is still hydrated.
It  is important to keep in mind that TVR discontinuation inmate  any skin reactions, but also to avoid stopping treatment
if  unnecessary. The ﬁnal decision might take in account the
clinical  evaluation of a dermatologist.
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Gastrointestinal  disorders  with  BOC  and  TVR
Dysgeusia, usually a metallic taste, has an increased fre-
quency  in patients receiving BOC and PegIFN/RBV (35% in
SPRINT-1  and -2; 44% in RESPOND-2) compared with patients
receiving  SOC alone (16% in SPRINT-1 and -2; 11% in RESPOND-
2).11,13,25 AEs such as dry mouth, nausea, vomiting and
diarrhea were  observed with BOC regimen, but diarrhea and
vomiting  were  more  common in patients with TVR regimen
compared to SOC.
Anorectal  symptoms occurred more  frequently in
TVR  (26.2%) compared with control arms (5.4%) in TVR
trials.10,12,22 The symptoms included hemorrhoids, anal
pruritus/discomfort or rectal burning usually within the ﬁrst
two  weeks of TVR therapy. Most events were  mild/moderate
and rarely lead to discontinuation of HCV treatment. All
symptoms  were  resolved after interruption of TVR.
The  mechanisms to explain anorectal symptoms are
unknown and no association with dermatological AEs has
been  evident. Patients should undergo anal examination
pre-treatment in order to exclude previous local lesions.
Symptomatic and non-speciﬁc care may  be considered for
managing  anorectal disorders, including topical corticoste-
roids  and systemic antihistamine in case of pruritus.
Drug  interactions  with  BOC  and  TVR
The adequate concentration of DAAs is critical to HCV treat-
ment  success. Drug interactions with potential to decrease
DAAs  levels can result in lower efﬁcacy and development
of drug resistance.18,19,30 In contrast, drug–drug interactions
that increase DAAs levels and exposure increase also the
risk  of AEs. Hence, the effective management of drug–drug
interactions is essential to optimize the beneﬁts of treat-
ment  of patients infected with HCV genotype 1.18 Therefore,
physicians should explore carefully the history of drugs use
prescribed  or not and also plant-based agents. Physicians
are  also advised to consult the available databases regarding
potential  drug–drug interactions.
The  knowledge of the main mechanisms of drug inter-
actions contributes to assess the risk and to implement
appropriate actions in order to avoid their occurrence.
Pharmacokinetic interactions involving changes in
metabolism are the most important drug interactions.
The CYP enzymes are responsible for the most part of drug
metabolism. As a consequence, the most frequent and
important mechanism for drug interactions is CYP inhibition,
with  potential to promote high levels of drugs and related
toxicity.29,30 To date, most drug interactions with new DAAs
originate from in vitro studies, case reports and clinical
suspicion. Some interactions are theoretical.
About 60% of medications are metabolized by CYP3A, thus
several  drug interactions must be considered with BOC and
TVR  as they are both substrates and inhibitors of CYP3A29,31
(Table 3).
BOC  is metabolized by aldoketoreductase (AKR) 1C2 and
1C3  and, to a lesser extent, by oxidative metabolism mediated
by  CYP3A4/5. As BOC utilizes multiple routes of metabolism,
it  is less prone to drug interactions.31,32 The primary route of 1 3;1  7(2):194–204
metabolism of TVR is CYP3A4. This drug has low potential to
induce CYP2C, 3A, or 1A.
In  addition to interactions mediated by CYP3A, TVR and
BOC  are susceptible to interactions membrane transporter-
mediated. Both agents are substrates and inhibitors of
P-glycoprotein (P-gp) and can inhibit or saturate this trans-
porter,  thus increasing the concentrations of substrates.29,31,32
Table 4 lists the main substrates, inhibitors and inducers of the
CYP3A4.
Antiretroviral  drugs
Several commonly used antiretroviral drugs to treat HIV affect
the  CYP3A metabolic pathway or are its substrates.31,33 Con-
comitant  administration of TVR and efavirenz resulted in
reduced  steady-state exposure of both drugs. However, by
increasing  the TVR dose from 800 mg  to 1125 mg  every 8 h (i.e.
50%),  TVR exposure can be at least partially compensated. This
strategy has been successfully used in a phase 2a study in
HIV/HCV  coinfected patients.29,32
Ritonavir is used at a low dose (100 mg  once or twice daily)
to  inhibit CYP3A metabolism of other HIV PIs and enhance its
levels. This strategy was investigated for both BOC and TVR.
However,  ritonavir-boosting does not appear to decrease TVR
or BOC pill burden or dosing frequency.29,31
In clinical studies, administration of TVR with ritonavir-
boosted HIV PIs atazanavir, darunavir, fosamprenavir and
lopinavir  decreased the exposure to TVR. This effect was not
predicted,  as HIV PIs boosted with ritonavir inhibit CYP3A4
and  therefore may  be expected to increase TVR levels.29,32
Ritonavir-boosted atazanavir is the combination less
affected and is being studied in HIV/HCV coinfected patients
without  dose adjustment of either agent.29,31
Raltegravir is an attractive agent for use in the treatment
of  HIV in the HIV/HCV coinfected patients as its primary route
of  metabolism is glucuronidation and it does not inhibit or
induce  CYP enzymes. In combination with TVR, raltegravir
AUC  was  increased, presumably due to TVR inhibition of P-
gp.  Raltegravir has a wide therapeutic index and this increase
in  AUC is not expected to have clinical relevance.29 The risk
of  anemia is higher if zidovudine is used with BOC or TVR,
particularly in combination with RBV.32,33
Immunosuppressants
It is critical to determine the safest and most effective
doses of TVR or BOC to HCV-transplanted patients. However,
most  commonly used immunosupressors affect the CYP 3A
metabolic  pathway or are themselves substrates. These agents
have  narrow therapeutic windows and the impact of introduc-
ing  an agent with potential interaction such as BOC or TVR,
may  result in serious AEs.31 Preliminary data suggest that
cyclosporine may  be preferred to tacrolimus in the setting of
TVR  or BOC-based HCV treatment, but it may  still be possible
to  use tacrolimus in a very controlled manner.29Sirolimus is expected to behave similarly to tacrolimus, but
drug  interaction with DAAs has not been studied yet.29 The
longer  half-life of sirolimus (60 h), together with the signiﬁcant
anemia  caused by BOC or TVR could provide additive toxicity
b
 r
 a
 z
 j
 i
 n
 f
 e
 c
 t
 d
 i
 s
 .
 2
 0
 1
 3
;1
 7
(2
):194–204
 
199
Table 3 – Drug interactions with boceprevir (BOC) and telaprevir (TVR).
Co-administered
drug
Pharmacokinetic  parameters Comments/recommendations
Boceprevir Telaprevir Co-administered drug
AUC Cmax AUC Cmax AUC Cmax
Antiretroviral drugs
Efavirez ↓  19% ↓  8% ↓  26% ↓ 9% ↑ 20% (BOC) ↑ 11% (BOC) TVR and BOC: combination should be avoided; this may result in loss of
therapeutic effect.
Tenofovir ↑ 8% ↑ 5% – – ↑ 5% (BOC) ↑ 30% (TVR) ↑ 32%; (BOC)↑ 30% (TVR) TVR and BOC: no dosage adjustment necessary; clinical and laboratory
monitoring is recommended; discontinue tenofovir if adverse effects occur.
Protease inhibitor
Ritonavir (R) ↓ 19% ↓  27% ↓  24% ↓  15% –  – TVR: no dosage adjustment necessary (with atazanavir, raltegravir or
ritonavir).
Lopinavir + R –  – ↓ 32–54% ↓  53% ↑  (Minimal) –  TVR: combination should be avoided (with lopinavir, fosempravir or
darunavir) due to HCV/HIV treatment failure.
BOC: effects unknown.
Fosempravir + R – – ↓ 32% ↓ 33% ↓ 47–49% (TVR) ↓ 35–40% (TVR)
Darunavir + R – – ↓ 35% ↓ 36% ↓ 40–51% (TVR) ↓ 40–47% (TVR)
Atazanavir + R – – ↓ 20% ↓ 21% ↑ 17% (TVR) –
Raltegravir – – – – ↑ 31% (TVR) –
Antimicrobials
Rifampin – – ↓ 92% ↓ 86% – – TVR and BOC: combination should be avoided.
Rifabutin TVR and BOC: combination should be avoided.
Clarithromycin,
erythromycin
telithromycin
↑ ↑ ↑ TVR: caution is warranted and clinical monitoring is recommended.
BOC: no dosage adjustment necessary.
Antifungals
Ketoconazole ↑ 131% ↑ 41% ↑ 62% ↑ 24% ↑ 46–125% (TVR) ↑ 23–75% (TVR) BOC and TVR: doses of ketoconazole should not exceed 200 mg/day.
Itraconazole – – – – – – BOC and TVR: doses of itraconazole should not exceed 200 mg/day.
Voriconazole – – – – – – The interaction cannot be predicted.
Contraceptives
Drospirenone – – – – ↑ 99% (BOC) ↑ 57% (BOC) BOC: combination should be avoided.
Ethinyl estradiol (EE) – – – – ↓ 25% (BOTH) – TVR and BOC: non-hormonal contraception should be used.
Norethindrone – – – – ↓ 11% (TVR) – TVR: reduces norethindrone slightly.
Anxiolytics/sleep aids
Midazolam  oral – – – – ↑ 796% (TVR)↑ 430% (BOC) ↑177 (BOC) 186% (TVR) TVR and BOC: contraindicated.
Midazolam
intravenous
↑ 240% (TVR) ↑  2% (TVR) TVR:  contraindicated; BOC: halving the dose of intravenous midazolam could
be considered with monitoring for toxic effects.
Alprazolam – – – – ↑ 35% (TVR) – TVR: a lower dose of intravenous alprazolam should be considered; closely
monitor patient for respiratory depression and prolonged sedation.
Triazolam TVR: contraindicated (oral and intravenous); BOC: contraindicated (oral).
Zolpidem – – – – ↓ 42% (TVR) – TVR: a higher dose of zolpidem may be required; any dosage adjustments
made during concomitant TVR therapy should be re-adjusted following
completion of TVR therapy.
200
 
b
 r
 a
 z
 j
 i
 n
 f
 e
 c
 t
 d
 i
 s
 .
 2
 0
 1
 3
;1
 7
(2
):194–204
– Table 3 (Continued)
Co-administered
drug
Pharmacokinetic  parameters Comments/recommendations
Boceprevir Telaprevir Co-administered drug
AUC Cmax AUC Cmax AUC Cmax
Antidepressants
Escitalopram ↓ 35% (TVR);↓ 21% (BOC) ↓ 30% (TVR)
Immunosuppressants
Cyclosporine – – – – ↑ 364% (TRV) ↑ 32% (TRV) BOC and TVR: empirically reducing the cyclosporine dose by 75%, then using
therapeutic drug monitoring to further reﬁne the cyclosporine dose and
frequency; TVR ↑ the mean half life (12 h from baseline to 53 h). BOC: ↑
cyclosporine AUC (2.7-fold from baseline).
Tacrolimus – – – – ↑ 6900% (TRV) ↑ 835% (TRV) TVR and BOC: signiﬁcant dose reductions and prolongation of dosing interval
may be needed; close monitoring recommended; TVR ↑ the mean half life
(40 h from baseline to 196 h). BOC: ↑ tacrolimus AUC (17.1-fold from baseline).
Sirolimus – – – – ↑ ↑ Sirolimus is expected to behave similarly to tacrolimus.
Dexamethasone,
Prednisolone,
methyl-prednisolone
↓ ↓ – – TVR and BOC: co-administration with CYP3A4/5 inducers may decrease
antiretrovirals levels; if possible, the combination should be avoided; used
with caution if necessary.
Budesonide,
Fluticasone (inhaled)
–  – – – ↑ – BOC and TVR: if possible, the combination should be avoided; used with
caution if necessary; may result in ↑ plasma concentrations of the steroid,
causing signiﬁcantly reduced serum cortisol.
Anticonvulsants
Carbamazepine ↓ – ↓ – ↑ – TVR and BOC: if possible, the combination should be avoided; used with
caution if necessary and dose titration is recommended. Concentrations of
the  anticonvulsant may be altered and concentrations of TVR and BOC may
be  decreased.
Phenobarbital ↓ – ↓ – ↑ –
Phenytoin ↓ – ↓ – ↑ –
Anti-psychotics – There are reports of anti-psychotic toxicity when combined with CYP3A
inhibitor.
Aripiprazole – – – – ↑ – TRV and BOC: dosage of aripiprazole should be empirically reduced by half
when are initiated and the anti-psychotic dose then titrated to effect.
Quetiapine – – – – – – TRV and BOC: If possible, quetiapine use should be avoided.
Clozapine – – – – – – TRV and BOC: monitor carefully for QT interval prolongation and discontinue
clozapine if the QT interval exceeds 500 ms. Patients who experience
syncope,  dizziness or palpitations should have further evaluation, including
cardiac monitoring.
Pimozide – – – – – – TVR and BOC: contraindicated.
HMG-CoA reductase inhibitors
Atorvastatin –  – – – ↑ 688% (TVR) ↑ 960% (TVR) TVR: contraindicated; BOC: ↑ Cmax by 2.7-fold and AUC by 2.3-fold; monitor
patients for adverse effects (myopathy/rhabdomyolysis, elevated liver
enzymes) and the lowest dose should be used (20 mg atorvastatin).
Simvastatin – – – – ↑ ↑ TVR: contraindicated.
Lovastatin –  – – – ↑ ↑ TVR: contraindicated.
Rosuvastatin – – – – TVR and BOC: could be considered for use in combination with rosuvastatin;
has not been studied to date.
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– Table 3 (Continued)
Co-administered
drug
Pharmacokinetic  parameters Comments/recommendations
Boceprevir Telaprevir Co-administered drug
AUC Cmax AUC Cmax AUC Cmax
Angiotensin II receptor blocker
Irbesartan,  Losartan – – – – ↑ – TVR and BOC: dose reductions could be considered.
-Blockers
Carvedilol,
Nabivolol
– – – – ↑ – TVR and BOC: dose reductions could be considered.
Calcium channel blockers
Felodipine,
nifedipine,
nicardipine,
nisoldipine
– – – – – – TRV and BOC: clinical monitoring for adverse effects is recommended
(headache, peripheral edema, hypotension, tachycardia).
Amlodipine – – – – ↑ 179% (TVR) ↑ 27% (TVR) TVR: dose reductions could be considered in patients initiating antivirals; if
dose  adjustments are required, return to normal amlodipine dosing after
therapy with telaprevir has been completed.
Verapamil, diltiazem – – – – ↑ ↑ TRV: caution and clinical monitoring advised.
Antiarrhythmics
Amiodarone,
bepridil, quinidine,
ﬂecainide,
propafenone
– – – – ↑ ↑ TVR and BOC: caution and clinical monitoring is recommended; potential for
serious and/or life-threatening adverse events.
Other agents
Digoxin – – – – ↑ 85% (TVR) ↑ 50% (TVR) TVR and BOC: initial dose should be used with titration and monitoring of
serum digoxin concentrations.
Alfuzosin – – – – – – TVR: contraindicated; co-administration may result in which may result in
hypotension.
PDE-5 inhibitors
(sildenaﬁl, tadalaﬁl,
vardenaﬁl)
– – – – ↑ – TVR and BOC: contraindicated (for pulmonary arterial hypertension); lower
doses should be used; for erectile dysfunction increased monitoring for
adverse events (hypotension, visual abnormalities, syncope, and priapism).
Colchicine – – – – ↑ – TVR and BOC: a reduction in colchicine dosage or an interruption of
colchicine treatment (TVR) is recommended; avoid co-administration in
renal/hepatic impairment. Signiﬁcant increases in colchicine levels expected
with strong CYP3A4 inhibitors; fatal colchicine toxicity reported.
Warfarin – – – – ↑ or ↓ – TVR and BOC: INR must be monitored closely.
Ergot alkaloids TVR and BOC: contraindicated due to the potential for acute ergot toxicity
(e.g., peripheral vasospasm, ischemia of the extremities and/or other tissues)
Hypericum
perforatum
↓ – ↓ – – – TVR and BOC: contraindicated.
Adapted from: (1) Wilby31; (2) Seden33; (3) Kiser29; (4) Liapakis and Jacobson35; (5) Hézode18; (6) Seden and Back.32
(↑) increase; (↓) decrease; (–) no effect or unknown.
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Table 4 – Main substrates, inducers and inhibitors of cytochrome P450 3A4.
Substrates Inducers Inhibitors
Alfentanil Clarithromycin Ergotamine Indinavir Omeprazole Simvastatin Aminoglutethimide Amiodarone Nifedipine
Alfuzosin Clindamycin Erlotinib Isradipine Ondansetron Sirolimus Amprenavir Amprenavira Nilotinib
Aliskiren Clomipramine Erythromycin Itraconazole Oral Contraceptives Solifenacin Aprepitant Aprepitanta Norﬂoxacin
Almotriptan Clonazepam Escitalopram Ketoconazole Oxybutynin Sorafenib Carbamazepine Atazanavirb Pomegranate
Alprazolam Clopidogrel Esomeprazole Lapatinib Paclitaxel Sunitinib Dexamethasone Chloramphenicol Posaconazoleb
Amitriptyline Clozapine Estrogens, oral Lansoprazole Pantoprazole Tacrolimus Efavirenz Cimetidine Pazopanib
Amiodarone Cocaine Contraceptives Letrozole Pazopanib Tadalaﬁl Ethosuximide Ciproﬂoxacin Prednisone
Amlodipine Colchicine Eszopiclone Levobupivacaine Pimozide Tamoxifen Etravirine Clarithromycinb Propoxyphene
Amprenavir Cyclobenzaprine Ethinyl estradiol Lidocaine Pioglitazone Telithromycin Garlic supplements Cyclosporine Quinine
Aprepitant Cyclophosphamide Ethosuximide Lopinavir Prednisolone Temazepam Glucocorticoids Danazol Ranolazine
Asenapine Cyclosporine Etonogestrel Loratadine Prednisone Testosterone Glutethimide Delavirdine Ritonavirb
Atazanavir Dapsone Etoposide Losartan Progesterone/ Tiagabine Griseofulvin Diltiazema Saquinavirb
Atorvastatin Darifenacin Etravirine Lovastatin Progestins Tinidazole Modaﬁnil Darunavir/ritonavirb Synercid
Beclomethasone Darunavir Exemestane Maraviroc Propafenone Tipranavir Nafcillin Dronedaronea Telithromycinb
Bepridil Dasatinib Everolimus Methadone Propoxyphene Tolterodine Nevirapine Erythromycina Tipranavir/ritonavirb
Bexarotene Delavirdine Felodipine Methylprednisolone Quetiapine Tolvaptan Oxcarbazepine Ethinyl estradiol Verapamila
Bromocriptine Desogestrel Fentanyl Miconazole Quinidine Toremifene Phenobarbital Everolimus Voriconazoleb
Budesonide Dexamethasone Fesoterodine Midazolam Quinine Tramadol Phenytoin Fluconazolea Zaﬁrlukast
Buprenorphine Dextromethorphan Fexofenadine Mifepristone Rabeprazole Trazodone Primidone Fluoxetine
Buspirone Diazepam Finasteride Mirtazapine Ramelteon Triazolam Rifabutin Fluvoxamine
Busulfan Dihydroergotamine Flutamide Modaﬁnil Ranolazine Trimetrexate Rifampin Fosamprenavira
Cannabinoids Diltiazem Fluticasone Mometasone Repaglinide Valdecoxib Rifapentine Grapefruita
Caffeine Disopyramide Fluvestrant Montelukast Romidepsin Vardenaﬁl Ritonavir Indinavirb
Carbamazepine Docetaxel Galantamine Nateglinide Rifabutin Verapamil St. John’s wort Imatinib
Cevimeline Dofetilide Guanfacine Nefazodone Rifampin Vinblastine Isoniazid
Chlorpheniramine Dolasetron Haloperidol Nelﬁnavir Ritonavir Vincristine Itraconazoleb
Cilostazol Domperidone Hydrocodone Nevirapine Salmeterol Vinorelbine Ketoconazoleb
Ciclesonide (desciclesonide Donepezil Hydrocortisone Nicardipine Saquinavir Voriconazole Lapatinib
[active Metabolite]) Doxorubicin Ifosfamide Nifedipine Saxagliptin (r)-warfarin Methylprednisolone
Cinacalcet Dronabinol Iloperidone Nilotinib Sertraline Zaleplon Mifepristone
Cisapride Dronedarone Imatinib Nimodipine Sibutramine Zileuton Nefazodoneb
Citalopram Dutasteride Imipramine Nisoldipine Sildenaﬁl Ziprasidone Nelﬁnavirb
Efavirenz Ixabepilone Nitrendipine Silodosin Zolpidem Nicardipine
Eplerenone Norethindrone Zonisamide
Italics denote those substrates, inhibitors, and inducers that have been involved in a drug interaction of clinical relevance, and/or are associated with strong drug interaction warnings or recommen-
dations for speciﬁc intervention (i.e., dose alteration, laboratory monitoring, or avoidance). For many medications, strength of inhibition in vivo is undetermined.
a Moderate inhibitors (2- to <5-fold increase in exposure, or 50–80% decrease in clearance of substrate).
b Strong inhibitors (>5-fold increase in exposure, or >80% decrease in clearance of substrate).
 2 0 1 
a
p
H
S
o
r
c
i
m
u
O
b
s
v
w
O
R
i
o
m
m
p
t
f
a
f
e
c
b
b
p
P
T
a
t
a
i
r
o
b
a
q
f
b
i
d
i
e
sb r a z j i n f e c t d i s .
nd make concurrent therapy difﬁcult to manage in clinical
ractice.31
MG-CoA  reductase  inhibitors
imvastatin, atorvastatin and lovastatin are highly dependent
n  CYP3A for its metabolism and increasing reports alert to the
isk  of myopathy and rhabdomyolysis in patients with higher
oncentrations of simvastatin and atorvastatin caused by drug
nteractions with a potent CYP3A inhibitor.29,34
Pravastatin is metabolized by multiple pathways. The
echanism for the interaction of BOC with pravastatin is
nclear,  but may  be related to BOC related inhibition of
ATP1B1.29
Rosuvastatin is metabolized by CYP2C9 and 2C19 and could
e  considered for use in combination with BOC or TVR, but it
till needs to be conﬁrmed as unexpected increases in rosu-
astatin  concentrations have been reported in combination
ith  several HIV PIs.29
ral  contraceptives
BV is highly teratogenic and prevention of pregnancy during
ts  use is critical. Patients are advised to use at least two forms
f  birth control during treatment with Peg-IFN/RBV and for six
onths thereafter.29,35
The combination of BOC and TVR and ethinylestradiol
ay decrease the plasma concentrations of the drug with
otential  for failure of birth control. Systemic hormonal con-
raception  must be augmented by two alternative effective
orms  of contraception and may  include intrauterine devices
nd  barrier methods during therapy and for six months
ollowing BOC therapy.36 BOC increases drospirenone lev-
ls  and high concentrations of this drug can theoretically
ause hyperkalemia.29 In addition, based on a recent review
y  the FDA, drospirenone-containing birth control pills may
e  associated with higher risk for blood clots than other
rogestin-containing pills.34
sychotropic  medications
he selective serotonin reuptake inhibitors (SSRIs) are gener-
lly  the ﬁrst line treatment of depression in HCV patients due
o  their safety in overdose and improved tolerability. There
re  no obvious concentration-effect data for the SSRIs, so it
s unknown if reductions in exposures can be translated in
educed  ability to control depressive symptoms.29
There are no formal drug interaction studies between TVR
r  BOC and antipsychotics, thus predictions must be made
ased  on knowledge of the clinical pharmacology of each
gent.29
Midazolam is a selective CYP3A substrate. Flurazepam,
uazepam and triazolam are also highly dependent on CYP3A
or  metabolism and combination with TVR or BOC should
e  avoided.29 Lorazepam and oxazepam are not converted
nto  active metabolite and are only conjugated, thus these
rugs  could be considered for patients using IPs. Trazodone
s  also used as a sleep aid. With the HIV PI ritonavir, trazodone
xposures are increased, causing nausea, dizziness, hypoten-
ion  and syncope.293;1 7(2):194–204  203
Cardiovascular  drugs
CYP enzymes are not involved in the metabolism of ACE
inhibitors or diuretics. Among the beta blockers, only
carvedilol and nabivolol are metabolized to some extent by
CYP3A4.  There is a contribution of CYP3A4 to the metabolism
of  angiotensin II receptor blockers irbesartan and losartan.
The  calcium channel blockers are highly dependent on CYP3A
for  metabolism and are therefore susceptible to increases in
exposure with BOC or TVR.29
BOC and TVR are both substrates and inhibitors of P-gp.
Digoxin is not metabolized, but is a selective substrate of P-gp.
TVR  can increase the exposure of digoxin and it was  thought
to  result from inhibition or saturation of P-gp in the gut rather
than  at a systemic level.29,32
Amiodarone is a substrate of many  CYP enzymes, but the
main  isoenzyme is CYP 3A4. It is advised to monitor amio-
darone  plasma concentrations and the patient for adverse
effects  related to amiodarone, including nausea, vomiting,
visual  changes, and cardiac arrhythmias if coadministration
with BOC is required.36
Antimicrobials  and  antifungals
Ketoconazole, itraconazole and voriconazole are strong CYP3A
inhibitors  (>5-fold increase in exposure, or >80% decrease in
clearance of substrate). Fluconazole is a moderate inhibitor
(2-  to <5-fold increase in exposure or 50–80% decrease in
clearance of substrate).37 Conversely, ketoconazole and itra-
conazole  are metabolized only by CYP 3A4, ﬂuconazole is not
metabolized  by CYP and voriconazole is substrate of CYP 2C9,
2C19  and 3A4.
Other  agents
Although the interaction between colchicine and BOC or TVR
has  not been studied yet, an interaction between colchicine
and  clarithromycin, a strong CYP3A4 inhibitor, resulted in fatal
colchicine toxicity. It is advised to treat the gout ﬂare with
reduced  colchicine dose to 0.6 mg  tablet for one dose, followed
by  0.3 mg  one hour later, with the repeated dose no earlier than
3  days. For prophylaxis of gout ﬂare, reduction of colchicine
from  an original dose of 0.6 mg  twice daily to 0.3 mg  once daily
or  from an original dose of 0.6 mg  once daily to 0.3 mg once
every  other day is recommended. For the treatment of famil-
ial  Mediterranean fever, the maximum daily colchicine dose
should  be no more  than 0.6 mg  daily (0.3 mg  twice daily).36
Coadministration of BOC or TVR and domperidone may
result  in signiﬁcantly increased plasma concentrations of
domperidone, with risk of serious cardiac events (ventricular
arrhythmias and sudden cardiac death). Case–control stud-
ies  have demonstrated an association of serious ventricular
arrhythmias and sudden cardiac death, particularly with dom-
peridone  doses greater than 30 mg/day and in patients older
than  60 years. Domperidone should be initiated at the lowest
possible  dose and titrated with caution. It must be discon-
tinued  in the presence of dizziness, palpitations, syncope, or
seizure. Dosage adjustments made during concomitant use of
TVR  need readjusts after TVR therapy is completed.36
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